Taiwan Liposome Company announced Sept. 8 that it would become a private company in late September, about three years after launching a $22 million initial public offering of American Depositary Shares in the US on the Nasdaq Global Market. The company is developing a macular edema treatment candidate and other novel nanomedicines that combine the company’s BioSeizer proprietary lipid-assembled drug …
Novartis Announces Positive Results From Phase 3 Trials of Beovu in DME, Including Dosing Intervals Up to 16 Weeks
Novartis announced positive results from two phase 3 clinical trials assessing Beovu (brolucizumab) 6 mg versus aflibercept 2 mg in patients with diabetic macular edema (DME). Year 2 of the pivotal KITE trial evaluated Beovu on up to 16-week dosing intervals, and the 1-year KINGFISHER study evaluated Beovu dosed every 4 weeks.1,3 Both trials demonstrated an overall well-tolerated safety profile.
Oxurion Announces Publication of Positive Phase 1 Clinical Data Evaluating THR-687 for Treatment of DME
Oxurion announced that the positive phase 1 study of THR-687, a novel, highly potent integrin agonist for the treatment of DME has just been published in Ophthalmology Science. The multicenter, dose escalation study was designed to evaluate the safety and preliminary efficacy of three dose levels of THR-687 (0.4, 1.0 or 2.5mg) in subjects with center-involved DME following a single intravitreal …
Alimera Sciences and Tanner Pharma Group Initiate Global Named Patient Program for ILUVIEN®
Alimera Sciences Europe Limited announced the initiation of a Named Patient Program for ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19 mg globally for the treatment of diabetic macular edema (DME) and in Europe and the Middle East, for the treatment of non-infectious posterior uveitis (NIU-PS).
